Humanwell Healthcare (600079.SH) announced that its subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the marketing authorization of Midazolam Injection.
The approved indications for Midazolam Injection include: 1) Conscious sedation before, during, or after diagnostic or therapeutic procedures (with or without local anesthesia); 2) Premedication before anesthesia induction in adults, anesthesia induction, and combined use with other anesthetics for sedation; premedication before anesthesia induction in children; 3) Sedation in intensive care units (ICU).
Comments